Dong-A ST is facing a new wave of change. With the appointment of Jae-Hong Park as president and chief scientific officer last year, some of these changes may be more fundamental than those at its South Korean rivals.
Dong-A ST Faces New Wave Of Change As It Challenges Norms
Park Looks To Shake Up 'Outdated' R&D Approaches
Dong-A ST’s president of R&D Jae-Hong Park talks to Scrip about the changes needed in the domestic pharma sector and wider industry if Korean biopharma firms are to step up to global levels.
